| Authors: |
Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: dwells@parkerici.org., van Buuren MM; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; T Cell Immunology, Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech US, Cambridge, MA, USA., Dang KK; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Hubbard-Lucey VM; Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA., Sheehan KCF; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA., Campbell KM; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Lamb A; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Ward JP; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Sidney J; Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA., Blazquez AB; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rech AJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Zaretsky JM; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Comin-Anduix B; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Surgery, David Geffen School of Medicine, Johnson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Ng AHC; Institute for Systems Biology, Seattle, WA, USA., Chour W; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA., Yu TV; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Rizvi H; Druckenmiller Center for Lung Cancer Research, MSKCC, New York, NY, USA., Chen JM; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Manning P; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Steiner GM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Doan XC; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Merghoub T; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Medicine, MSKCC, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Guinney J; Computational Oncology, Sage Bionetworks, Seattle, WA, USA; Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA., Kolom A; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA., Selinsky C; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Ribas A; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Hellmann MD; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Druckenmiller Center for Lung Cancer Research, MSKCC, New York, NY, USA; Department of Medicine, MSKCC, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Hacohen N; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Sette A; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Heath JR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Institute for Systems Biology, Seattle, WA, USA., Bhardwaj N; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ramsdell F; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Schreiber RD; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA., Schumacher TN; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Defranoux NA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: ndefranoux@parkerici.org. |
